List of Figures
Figure 1-1: Bispecific Antibodies - Advantages
Figure 2-1: Antibody-Chemotherapy Combination - Advantages
Figure 2-2: Antibody-Chemotherapy Combination - Impending Challenges
Figure 3-1: Blincyto - Mechanism of Action
Figure 3-2: Hemlibra - Mechanism of Action
Figure 3-3: Rybrevant - Mechanism of Action
Figure 3-4: Regulatory Designations - Benefits
Figure 4-1: Multiclonics - Distinctive Characteristics
Figure 4-2: Biclonics - Format
Figure 4-3: ADAPTIR Bispecific Structure
Figure 4-4: ADAPTIR-FLEX
Figure 4-5: BEAT Platform - Multispecific Antibodies
Figure 4-6: FIT-Ig - Proprietary Bispecific Platform
Figure 4-7: BiClone format
Figure 4-8: BioAtla CABs - Features
Figure 4-9: BioAtla CABs - Benefits
Figure 4-10: IMBiologic Bispecific Antibodies - Strategy
Figure 4-11: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 4-12: Novel HBICE
Figure 4-13: HBICE - Mechanism of Action 1
Figure 4-14: HBICE - Mechanism of Action 2
Figure 4-15: Phanes Therapeutics - PACbody Platform
Figure 4-16: Phanes Therapeutics - SPECpair Platform
Figure 4-17: Phanes Therapeutics - ATACCbody
Figure 4-18: Numab Therapeutics - Technology
Figure 4-19: Grabody I Platform - Mechanism of Action
Figure 4-20: Grabody I Platform - Mechanism of Action
Figure 4-21: 3-Step DuoBody Production Process
Figure 4-22: DuoHexaBody Molecules - Schematic
Figure 4-23: iTAb - Patented Structure
Figure 4-24: iTAb - Mechanism of Action
Figure 4-25: Synimmune - Proprietary Bispecific Antibody Format
Figure 4-26: BiTE - Structure
Figure 4-27: BiTE Molecule
Figure 4-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 4-29: ALiCE - Characteristics
Figure 4-30: ALiCE - Schematic Diagram & Mechanism of Action
Figure 4-31: Abz2 Bispecific Platform
Figure 4-32: Abz2 Bispecifics - Benefits
Figure 4-33: Neo-X-Prime Bispecific Mechanism
Figure 4-34: B-Body Bispecific Antibody - Structre
Figure 4-35: xLinkBsAb - Structure
Figure 4-36: PrecisionGATE Bispecific Antibody - Structure
Figure 5-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-2: Global - Annual Bispecific Antibodies Market by Drugs (US$ Million), 2024
Figure 5-3: Global - Bispecific Antibodies Market Shares by Drugs (%), 2024
Figure 5-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2024
Figure 5-5: Global - Annual Bispecific Antibody Market by Region (US$ Million), 2024
Figure 5-6: Global - Bispecific Antibody Market Shares by Region (%), 2024
Figure 5-7: US -Bispecific Antibody Market (US$ Million), 2020-2024
Figure 5-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-9: US - Quarterly Bispecific Antibodies Market (US$ Million),2023
Figure 5-10: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2024
Figure 5-11: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2024
Figure 5-12: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2023
Figure 5-13: Global - Bispecific Antibodies Market by Drug (US$ Million), 2023
Figure 5-14: Global - Bispecific Antibodies Market Shares by Drugs (%), 2023
Figure 5-15: Global - Quarterly Bispecific Antibody Market (US$ Million), 2023
Figure 5-16: Global - Bispecific Antibody Market by Region (US$ Million), 2023
Figure 5-17: Global - Bispecific Antibody Market Shares by Region (%), 2023
Figure 5-18: Blincyto - Total Treatment Cost & Reimbursement Cost
Figure 5-19: Blincyto - in Pocket & Out of Pocket Cost of Treatment
Figure 5-20: Hemlibra - Total Treatment Cost & Reimbursement Cost
Figure 5-21: Hemlibra - in Pocket & Out of Pocket Cost of Treatment
Figure 5-22: Rybrevant - Maximum Coverage by Medicaid (US$), 2023
Figure 5-23: Rybrevant - Maximum Coverage by Private Insurance Coverage (US$), 2021
Figure 5-24: Vabysmo - Total Treatment Cost & Reimbursement Cost
Figure 5-25: Vabysmo - in Pocket & Out of Pocket Cost of Treatment
Figure 5-26: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
Figure 6-1: US - Bispecific Antibodies Approval
Figure 7-1: Bispecific Antibodies - Advantages
Figure 7-2: HX009-II-02 Phase 1/2 Study - Initiation & Completion Year
Figure 7-3: Bispecific Antibodies - Future Opportunities in Melanoma
Figure 7-4: Mim8 Phase 3 (NCT05878938) Study - Initiation & Completion Year
Figure 7-5: NXT007 Phase 1/2 (NCT05987449) Study - Initiation & Completion Year
Figure 7-6: HMB-001 Phase 1/2 (NCT06211634) Study - Initiation & Completion Year
Figure 8-1: Blincyto - Approval Year by Region
Figure 8-2: Blincyto - Patent Filing & Expiration Year
Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 8-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles For Treatment of MRD-Positive B-Cell Precursor (Days)
Figure 8-5: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
Figure 8-6: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2024
Figure 8-8: Global - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-9: Global - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-10: Blincyto - Sales by Region (US$ Million), 2024
Figure 8-11: Blincyto - Sales by Region (%), 2024
Figure 8-12: Blincyto - Sales by Region (US$ Million), 2023
Figure 8-13: Global - Blincyto Sales by Region (%), 2023
Figure 8-14: US - Blincyto Sales ((US$ Million), 2020-2024
Figure 8-15: US - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-16: US - Blincyto Sales Quaterly (US$ Million), 2023
Figure 8-17: ROW - Blincyto Sales (US$ Million), 2020-2024
Figure 8-18: ROW - Blincyto Sales Quaterly (US$ Million), 2024
Figure 8-19: ROW - Blincyto Sales Quaterly (US$ Million), 2023
Figure 9-1: Hemlibra - Approval Years by Region
Figure 9-2: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), March’2025
Figure 9-3: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), March’2025
Figure 9-4: Hemlibra - Recommended Loading & Maintenance Dose For Treatment of Hemophilia (mg/kg/Week)
Figure 9-5: Global - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-6: Global - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-7: Global - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-8: US - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-9: US - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-10: US - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-11: Europe - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-12: Europe - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-13: Europe - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-14: Japan - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-15: Japan - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-16: Japan - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-17: ROW - Hemlibra Sales (US$ Million), 2020-2024
Figure 9-18: ROW - Hemlibra Sales Quaterly (US$ Million), 2024
Figure 9-19: ROW - Hemlibra Sales Quaterly (US$ Million), 2023
Figure 9-20: Global - US v/s ex-US Sales (US$ Million), 2024
Figure 9-21: Global - Hemlibra Annual Sales by Region (US$ Million), 2024
Figure 9-22: Global - Hemlibra Sales by Region (%), 2024
Figure 9-23: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 9-24: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
Figure 9-25: Global - Hemlibra Sales by Region (%), 2023
Figure 10-1: Rybrevant - Patent Filing & Expiration Year
Figure 10-2: Rybrevant - Price Per Unit & Supply of Intravenous Solution (US$), March’2025
Figure 10-3: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 10-4: Rybrevant - Dose Reduction in Patients With Weight Less Than 80 kg (mg)
Figure 10-5: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 11-1: Vabysmo - Approval Year by Region
Figure 11-2: Rybrevant - Patent Filing & Expiration Year
Figure 11-3: Vabysmo - Price Per Unit & Supply of Intravitreal Solution (US$), March’2025
Figure 11-4: Global - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-5: Global - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-6: Global - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-7: US - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-8: US - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-9: US - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-10: Europe - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-11: Europe - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-12: Europe - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-13: Japan - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-14: Japan - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-15: Japan - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-16: ROW - Vabysmo Sales (US$ Million), 2022-2024
Figure 11-17: ROW - Vabysmo Sales Quaterly (US$ Million), 2024
Figure 11-18: ROW - Vabysmo Sales Quaterly (US$ Million), 2023
Figure 11-19: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2024
Figure 11-20: Global - Vabysmo Annual Sales by Region (US$ Million), 2024
Figure 11-21: Global - Vabysmo Sales by Region (%), 2024
Figure 11-22: Global - Vabysmo US v/s Ex-US Sales (US$ Million), 2023
Figure 11-23: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
Figure 11-24: Global - Vabysmo Sales by Region (%), 2023
Figure 12-1: Lunsumio - Approval Years by Region
Figure 12-2: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March’2025
Figure 12-3: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March’2025
Figure 12-4: Global - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-5: Global - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-6: Global - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-7: US - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-8: US - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-9: US - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-10: Europe - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-11: Europe - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-12: Europe - Lunsumio Sales Quaterly (US$ Million), 2023
Figure 12-13: ROW - Lunsumio Sales (US$ Million), 2022-2024
Figure 12-14: ROW - Lunsumio Sales Quaterly (US$ Million), 2024
Figure 12-15: Lunsumio - US v/s Ex-US Sales (US$ Million), 2024
Figure 12-16: Global - Lunsumio Annual Sales by Region (US$ Million), 2024
Figure 12-17: Global - Lunsumio Sales by Region (%), 2024
Figure 12-18: Global - US v/s Ex-US Sales (US$ Million), 2023
Figure 12-19: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
Figure 12 20: Global - Lunsumio Sales by Region (%), 2023
Figure 13-1: China - Kaitani Sales (US$ Million), 2022-2023
Figure 13-2: China - Kaitani Sales (US$ Million), H1-H2’2023
Figure 14-1: Tecvayli - Approval Years by Region
Figure 14-2: Tecvayli - Patent Acceptance & Expiration Year
Figure 14-3: US - Cost Per Unit & Supply of Tecvayli Subcutaneous Solution (US$), March’2025
Figure 14-4: EU - Cost of Supply of Tecvayli Subcutaneous Solution (US$), March’2025
Figure 14-5: Global - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-6: Global - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-7: Global - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-8: US - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-9: US - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-10: US - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-11: ROW - Tecvayli Sales (US$ Million), 2022-2024
Figure 14-12: ROW - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 14-13: ROW - Tecvayli Sales Quaterly (US$ Million), 2023
Figure 14-14: Tecvayli - US v/s Ex-US Sales (US$ Million), 2024
Figure 14-15: Tecvayli - US v/s Ex-US Sales (%), 2024
Figure 14-16: Tecvayli - US v/s Ex-US Sales (US$ Million), 2023
Figure 14-17: Tecvayli - US v/s Ex-US Sales (%), 2023
Figure 15-1: Columvi - Approval Year by Region
Figure 15-2: US - Price Per Unit & Supply of Columvi Intravenous Solution (US$), March’2025
Figure 15-3: EU - Price of Supply of Columvi Intravenous Solution (US$), March’2025
Figure 15-4: Global - Columvi Sales (US$ Million), 2023-2024
Figure 15-5: Global - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-6: Global - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-7: US - Columvi Sales (US$ Million), 2023-2024
Figure 15-8: US - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-9: US - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-10: Europe - Columvi Sales (US$ Million), 2023 & 2024
Figure 15-11: Europe - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-12: Europe - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-13: ROW - Columvi Sales (US$ Million), 2023 & 2024
Figure 15-14: ROW - Columvi Sales Quaterly (US$ Million), 2024
Figure 15-15: ROW - Columvi Sales Quaterly (US$ Million), 2023
Figure 15-16: Global - Columvi US v/s Ex-US Sales (US$ Million), 2024
Figure 15-17: Global - Columvi Annual Sales by Region (US$ Million), 2024
Figure 15-18: Global - Columvi Sales by Region (%), 2024
Figure 15-19: Global - Columvi US v/s Ex-US Sales (US$ Million), 2023
Figure 15-20: Global - Columvi Annual Sales by Region (US$ Million), 2023
Figure 15-21: Global - Columvi Sales by Region (%), 2023
Figure 16-1: Epkinly - Approval Year by Region
Figure 16-2: US - Cost Per Unit & Supply of Epkinly Subcutaneous Solution (US$), March’2025
Figure 16-3: EU - Cost of Supply of Epkinly Subcutaneous Solution (US$), March’2025
Figure 16-4: Global - Epkinly Sales (US$ Million), 2023 & 2024
Figure 16-5: Global - Epkinly Sales Reported by Genmab (US$ Million), 2023 & 2024
Figure 16-6: Global - Epkinly Sales Reported by AbbVie (US$ Million), 2023 & 2024
Figure 16-7: Global - Epkinly Sales by Company (US$ Million), 2024
Figure 16-8: Global - Epkinly Sales by Company (US$ Million), 2023
Figure 17-1: Talvey - Approval Year by Region
Figure 17-2: Talquetamab - FDA & EMA Designation Year
Figure 17-3: Talvey - Patent Acceptance & Expiration Year
Figure 17-4: US - Price Per Unit & Supply of Talvey Intravenous Solution (US$), March’2025
Figure 17-5: EU - Price Per Supply of Talvey Intravenous Solution (US$), March’2025
Figure 18-1: Elrexfio - Approval Year by Region
Figure 18-2: Elranatamab - FDA & EMA Designation Year
Figure 18-3: US - Price Per Unit & Supply of Elrexfio Subcutaneous Solution (US$), March’2025
Figure 18-4: Global - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 18-5: US - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 18-6: ROW - Elrexfio Sales (US$ Million), 2023 & 2024
Figure 19-1: Imdelltra - Approval Year by Region
Figure 19-2: US - Price of Supply of Imdelltra Intravenous Powder (US$), March’2025
Figure 19-3: EU - Price of Supply of Imdelltra Intravenous Powder (US$), March’2025
Figure 19-4: Global - Imdelltra Sales (US$ Million), 2024
Figure 19-5: Global - Imdelltra Sales Quaterly (US$ Million), 2024
Figure 21-1: Global - Ordspono Sales (US$ Million), 2022-2024
Figure 21-2: Global - Ordspono Sales Quaterly (US$ Million), 2024
Figure 22-1: US - Price Per Unit & Supply of Ziihera (US$), March’2025
Figure 22-2: Global - Ziihera Sales (US$ Million), 2024
Figure 23-1: Zenocutuzumab - Active Patents